Pacira BioSciences, Inc. — Director's Dealing 2017

May 18, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pacira Pharmaceuticals, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2017-05-15

Reporting Person: Williams Kristen Marie (CAO and General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-05-15	Common Stock	M	3125	$9.25	Acquired	18775	Direct
2017-05-15	Common Stock	M	5937	$10.52	Acquired	24712	Direct
2017-05-15	Common Stock	M	11979	$10.81	Acquired	36691	Direct
2017-05-15	Common Stock	S	21041	$50.86	Disposed	15650	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-15	Stock Option (Right to Buy)	$9.25	M	3125	Disposed	2021-10-19	Common Stock (3125)	Direct
2017-05-15	Stock Option (Right to Buy)	$10.52	M	5937	Disposed	2022-03-02	Common Stock (5937)	Direct
2017-05-15	Stock Option (Right to Buy)	$10.81	M	11979	Disposed	2022-06-05	Common Stock (11979)	Direct

Footnotes

F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.75 to $51.00, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and as to the remaining option shares in successive equal monthly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.